ALBT | tickerfilter.com

Fundamental analysis

31%

Profitability 35%

Dept financing 43%

Liquidity 5%

Performance 30%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

2.40%

1 Month

29.58%

3 Months

-33.56%

6 Months

-61.07%

1 Year

-83.30%

2 Year

138.16%

Key data

Stock price

$0.92

P/E Ratio

0.00

DAY RANGE

$0.87 - $0.96

EPS

-$9.53

52 WEEK RANGE

$0.42 - $7.89

52 WEEK CHANGE

-$83.30

MARKET CAP

9.685 M

YIELD

N/A

SHARES OUTSTANDING

0.000

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-30-2025

BETA

-1.00

PUBLIC FLOAT

AVERAGE 10 VOLUME

$51,485,059

AVERAGE 30 VOLUME

$18,206,740

Company detail

CEO: David K. Jin
Region: US
Website: http://www.avalon-globocare.com/
Employees: 5
IPO year: 2018

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Avalon GloboCare Corp. owns and operates commercial real estate properties in the United States and the People's Republic of China. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia. It is also developing RNA-based FASH-CARTM cell therapy platform.

ALBT - Avalon GloboCare Corp.